<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00728182</url>
  </required_header>
  <id_info>
    <org_study_id>3302 (NA-1-002)</org_study_id>
    <nct_id>NCT00728182</nct_id>
  </id_info>
  <brief_title>Evaluating Neuroprotection in Aneurysm Coiling Therapy</brief_title>
  <acronym>ENACT</acronym>
  <official_title>A Phase II, Multicenter, Randomized, Fasting, Double-Blind, Placebo-Controlled, Safety, Tolerability and Efficacy Study Evaluating a Single Dose of Intravenous NA-1 in Male and Female Patients Undergoing Endovascular Repair of Brain Aneurysms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NoNO Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Arbor Vita Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>NoNO Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, single-dose, design investigating the
      safety, tolerability and efficacy of NA-1, a peptide designed to reduce ischemic brain
      damage. Up to 200 male and female patients undergoing endovascular repair of brain aneurysm
      will be dosed with 2.60 mg/kg of NA-1 or placebo as a 10 minute intravenous infusion after
      completion of the endovascular procedure on Day 1 of the study period. Subjects will undergo
      interim procedures Days 2-4 and end-of study procedures on Day 30. Standard safety criteria
      will be analysed. Efficacy endpoints include the ability of NA-1 to: 1) reduce the volume of
      ischemic embolic strokes, 2) reduce the number of ischemic embolic strokes, 3) reduce
      vascular cognitive impairment, and 4) reduce the frequency of large strokes induced by the
      endovascular procedure. The plasma concentrations of NA-1 will also be analyzed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Volume of New FLAIR Lesions(MRI)</measure>
    <time_frame>Enrolment, Days 2-4</time_frame>
    <description>Volume of new ischemic lesions as defined by FLAIR MRI at 12-95 hours postdose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of New DWI Lesions (MRI)</measure>
    <time_frame>Enrolment, Day 2-4</time_frame>
    <description>Number of new ischemic lesions as defined by DWI MRI at 12-95 hours postdose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of New FLAIR Lesions (MRI)</measure>
    <time_frame>Enrolment, Days 2-4</time_frame>
    <description>Number of new ischemic lesions as defined by FLAIR MRI at 12-95 hours postdose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of New DWI Lesions (MRI)</measure>
    <time_frame>Enrolment, Days 2-4</time_frame>
    <description>Volume of new DWI lesions as defined by MRI at 12-95 hours postdose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Institutes of Health Stroke Scale (NIHSS).</measure>
    <time_frame>Enrolment, Day 30</time_frame>
    <description>The NIHSS is a standardized neurological method to measure disability and recovery after stroke. Scores range from 0 to 42, with higher scores indicating increasing severity. Scores were dichotomized into 0-1 (good outcome) versus 2 or above. The number of participants scoring 0-1 on the NIHSS at Day 30 was compared for both groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale (mRS).</measure>
    <time_frame>Enrolment, Day 30</time_frame>
    <description>The mRS is a measure of global disability that has been widely applied for evaluating recovery from stroke. Scores range from 0 to 6, with higher scores indicating greater disability. A score of 0 indicates no residual symptoms; 1 = no significant disability/able to carry out all usual activities, despite some symptoms; 2 = slight disability; 3 = moderate disability; 4 = moderately severe disability; 5 = severe disability; 6 = death. The number of participants scoring 0-2 on the mRS at Day 30 was compared in both treatment groups.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Volume of New FLAIR Lesions (MRI) - Ruptured Aneurysm Subjects</measure>
    <time_frame>Enrolment, Days 2-4</time_frame>
    <description>Volume of new ischemic lesions as defined by FLAIR MRI at 12-95 hours postdose (pre-specified subgroup analysis)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of New DWI Lesions (MRI) - Ruptured Aneuryms Subjects</measure>
    <time_frame>Enrolment, Day 2-4</time_frame>
    <description>Number of new ischemic lesions as defined by DWI MRI at 12-95 hours postdose(pre-specified subgroup analysis)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of New FLAIR Lesions (MRI) - Ruptured Aneurysm Subjects</measure>
    <time_frame>Enrolment, Day 2-4</time_frame>
    <description>Number of new ischemic lesions as defined by FLAIR MRI at 12-95 hours postdose(pre-specified subgroup analysis)</description>
  </other_outcome>
  <other_outcome>
    <measure>Volume of New DWI Lesions (MRI) - Ruptured Aneurysm Subjects</measure>
    <time_frame>Enrolment, Day 2-4</time_frame>
    <description>Volume of new DWI lesions as defined by MRI at 12-95 hours postdose(pre-specified subgroup analysis)</description>
  </other_outcome>
  <other_outcome>
    <measure>National Institutes of Health Stroke Scale (NIHSS) - Ruptured Aneurysm Subjects</measure>
    <time_frame>Enrolment, Day 30</time_frame>
    <description>The NIHSS is a standardized neurological method to measure disability and recovery after stroke. Scores range from 0 to 42, with higher scores indicating increasing severity. Scores were dichotomized into 0-1 (good outcome) versus 2 or above. The number of participants scoring 0-1 on the NIHSS at Day 30 was compared for participants with ruptured aneurysms in both treatment groups(pre-specified subgroup analysis).</description>
  </other_outcome>
  <other_outcome>
    <measure>Modified Rankin Scale (mRS)- Ruptured Aneurysm Subjects</measure>
    <time_frame>Enrolment, Day 30</time_frame>
    <description>The mRS is a measure of global disability that has been widely applied for evaluating recovery from stroke. Scores range from 0 to 6, with higher scores indicating greater disability. A score of 0 indicates no residual symptoms; 1 = no significant disability/able to carry out all usual activities, despite some symptoms; 2 = slight disability; 3 = moderate disability; 4 = moderately severe disability; 5 = severe disability; 6 = death. The number of participants scoring 0-2 on the mRS at Day 30 with ruptured aneurysms was compared in both treatment groups(pre-specified subgroup analysis).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">185</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>NA-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 amino acid peptide that consists of a 9 amino acid domain that inhibits PSD-95 and a 11 amino acid domain than enables the peptide to cross the blood-brain barrier.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NA-1</intervention_name>
    <description>single intravenous dose of 2.6 mg/kg of NA-1 administered as a 10-minute infusion</description>
    <arm_group_label>NA-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>single intravenous dose of 2.6 mg/kg of placebo administered as a 10-minute infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  A diagnosis of a ruptured or unruptured brain aneurysm deemed suitable for repair by
             neuroendovascular techniques involving intraluminal occlusion by detachable platinum
             coils, stent-assisted coiling, pipeline stent, balloon-assisted coiling, covered stent
             only, neck-bridge device, re-coiling, or re-treatment of a previously coiled/treated
             aneurysm. There are no restrictions on adjunctive devices. For patients with a
             ruptured aneurysm, endovascular repair must take place within 72 hours of the ictal
             haemorrhage.

          -  If the aneurysm has ruptured, patient should be Grade I-III on the World Federation of
             Neurological Surgeons (WFNS) grading scale for subarachnoid hemorrhage. If the patient
             is intubated but alert and able to follow commands (at least a 2-step command), and is
             not kept intubated for neurological status (i.e., WFNS Grade IV or V), the patient is
             considered WFNS Grade III and is eligible for the trial.

          -  Absence of ongoing ischemic symptoms such as transient ischemic attacks, minor
             strokes, stroke-in-evolution, or clinical evidence of cerebral vasospasm within 2
             weeks prior to randomization. (If a CT scan, cerebral angiogram, or other imaging
             performed during the 2 weeks prior to randomization shows radiological vasospasm
             deemed by the treating physician to be potentially clinically significant, the subject
             is excluded.)

          -  Brain MRI imaging (DWI and FLAIR sequences) within 2 weeks prior to the endovascular
             aneurysm repair procedure as detailed in Section 8.2. Imaging must not demonstrate any
             focal ischemic stroke defined as a new region of restricted diffusion and/or a focal
             area of reduced perfusion on a relative mean transit time (rMTT) or relative time to
             peak (rTTP) map

          -  Male or female with a minimum age of 18 years on the day of enrolment.

          -  Female subjects of childbearing potential: Negative pregnancy test. After enrolment,
             blood will be drawn from women of childbearing potential for a confirmatory test of
             pregnancy as evaluated by a serum B-hCG test. The definition of non-childbearing
             potential includes the following:

               -  Surgically sterile (e.g., hysterectomy with or without oophorectomy; fallopian
                  tube ligation; endometrial ablation), at least 30 days prior to signature of the
                  Informed Consent form

               -  At least 5 years post-menopause (i.e., 6 years post last menstrual period), or
                  menopause confirmed by follicle-stimulating hormone (FSH) testing. Non-surgically
                  sterile females or females with undocumented post-menopausal status must be
                  willing to use a medically approved method of birth control for 3 months after
                  completion of dosing.

          -  Non-surgically sterile males or males with partners of childbearing potential must be
             willing to use condoms with spermicide for 3 months after completion of dosing.

          -  Body weight less than or equal to 180 kg.

          -  Normal or abnormal but not clinically significant findings in the

               -  non-neurological physical examination

               -  12-lead ECG

               -  PQ or PR interval less than or equal to 210 msec;

               -  In unruptured aneurysm cases, QTc interval less than 450 msec for males or 470
                  msec for females. For ruptured aneurysm cases, QTc interval is not restricted.

               -  vital signs

               -  blood pressure between 80-180/50-100 mm Hg,

               -  body temperature less than or equal to 38.5oC

          -  Informed consent and availability of the subject for the entire study period and
             willingness of the subject to adhere to protocol requirements, as evidenced by a
             signed Informed Consent Form.

        Exclusion Criteria

          -  Dissecting or mycotic brain aneurysm. Fusiform or atherosclerotic intracerebral
             aneurysms may be eligible for the trial if endovascular treatment is planned with a
             goal of exclusion of the aneurysm from the circulation.

          -  Planned endovascular vessel sacrifice as the primary modality for aneurysm treatment.

          -  Known history of life-threatening allergic reaction to any medication.

          -  Chronic renal disease defined as a baseline serum creatinine &gt; 150 umol/L.

          -  Women who are pregnant, or have a positive urine or blood (β-hCG) pregnancy test.

          -  Women who are breastfeeding.

          -  Any clinically significant psychiatric or psychological disease, which would preclude
             the patient from completing the protocol.

          -  Pre-morbid (estimated) modified Rankin scale score of greater than 2.

          -  Previous serious traumatic brain injury that would preclude the patient from
             completing the protocol or preclude MRI analysis of small strokes.

          -  Patients with known HIV infection.

          -  Patients who are unable to have an MRI scan for any reason.

          -  Participation in a clinical trial with an investigational drug within 30 days
             preceding this study. Previous participation in the ENACT trial (e.g,, to treat a
             prior aneurysm), participation in another trial involving NA-1 or prior receipt of
             NA-1.

          -  Any other medical condition that the site investigator deems would put the patient at
             excessive risk of participation in the study or an expected life expectancy less than
             1 year or that would result in inability to collect clinical outcomes at 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Hill, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Foothills Medical Centre, University of Calgary</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foothills Medical Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QEII Health Sciences Centre - Halifax Infirmary</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences General Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8X 2S2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital - Civic Campus</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 2W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Notre-Dame du Centre Hospitalier de l`Université de Montréal (CHUM)</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de l'Enfant Jesus</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1J 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal University Hospital</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hill MD, Martin RH, Mikulis D, Wong JH, Silver FL, Terbrugge KG, Milot G, Clark WM, Macdonald RL, Kelly ME, Boulton M, Fleetwood I, McDougall C, Gunnarsson T, Chow M, Lum C, Dodd R, Poublanc J, Krings T, Demchuk AM, Goyal M, Anderson R, Bishop J, Garman D, Tymianski M; ENACT trial investigators. Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2012 Nov;11(11):942-50. doi: 10.1016/S1474-4422(12)70225-9. Epub 2012 Oct 8.</citation>
    <PMID>23051991</PMID>
  </results_reference>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2008</study_first_submitted>
  <study_first_submitted_qc>August 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2008</study_first_posted>
  <results_first_submitted>May 8, 2013</results_first_submitted>
  <results_first_submitted_qc>August 9, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 17, 2013</results_first_posted>
  <last_update_submitted>August 9, 2013</last_update_submitted>
  <last_update_submitted_qc>August 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stroke</keyword>
  <keyword>Vascular cognitive impairment</keyword>
  <keyword>Coiling</keyword>
  <keyword>Endovascular repair</keyword>
  <keyword>Brain aneurysm</keyword>
  <keyword>NA-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between September 16, 2008 and March 30, 2011, subjects were recruited to 10 hospitals in Canada and 3 in the United States.</recruitment_details>
      <pre_assignment_details>12 subjects were randomized into study but did not receive drug:5 due to do endovascular aneurysm repair, 3 due to inability to obtain a pre-procedure MRI,2 due to pre-procedure ECG showing a QTc interval &gt; 450 ms, 1 due to a fatal aneurysm rupture before drug, and 1 due to refusal by anesthesiologist to give drug to a subject with severe COPD.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>1 NA-1</title>
          <description>20 amino acid peptide that consists of a 9 amino acid domain that inhibits PSD-95 and a 11 amino acid domain than enables the peptide to cross the blood-brain barrier.
NA-1 : single intravenous dose of 2.6 mg/kg of NA-1 administered as a 10-minute infusion</description>
        </group>
        <group group_id="P2">
          <title>2 Placebo</title>
          <description>Placebo : single intravenous dose of 2.6 mg/kg of placebo administered as a 10-minute infusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="93"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1 NA-1</title>
          <description>20 amino acid peptide that consists of a 9 amino acid domain that inhibits PSD-95 and a 11 amino acid domain than enables the peptide to cross the blood-brain barrier.
NA-1 : single intravenous dose of 2.6 mg/kg of NA-1 administered as a 10-minute infusion</description>
        </group>
        <group group_id="B2">
          <title>2 Placebo</title>
          <description>Placebo : single intravenous dose of 2.6 mg/kg of placebo administered as a 10-minute infusion</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="92"/>
            <count group_id="B2" value="93"/>
            <count group_id="B3" value="185"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.72" spread="10.6"/>
                    <measurement group_id="B2" value="56.05" spread="10.3"/>
                    <measurement group_id="B3" value="56.88" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Volume of New FLAIR Lesions(MRI)</title>
        <description>Volume of new ischemic lesions as defined by FLAIR MRI at 12-95 hours postdose</description>
        <time_frame>Enrolment, Days 2-4</time_frame>
        <population>All study patients who received study drug and an analyzable MRI at 12-95 hours postdose.</population>
        <group_list>
          <group group_id="O1">
            <title>1 NA-1</title>
            <description>20 amino acid peptide that consists of a 9 amino acid domain that inhibits PSD-95 and a 11 amino acid domain than enables the peptide to cross the blood-brain barrier.
NA-1 : single intravenous dose of 2.6 mg/kg of NA-1 administered as a 10-minute infusion</description>
          </group>
          <group group_id="O2">
            <title>2 Placebo</title>
            <description>Placebo : single intravenous dose of 2.6 mg/kg of placebo administered as a 10-minute infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of New FLAIR Lesions(MRI)</title>
          <description>Volume of new ischemic lesions as defined by FLAIR MRI at 12-95 hours postdose</description>
          <population>All study patients who received study drug and an analyzable MRI at 12-95 hours postdose.</population>
          <units>mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="915" spread="5598"/>
                    <measurement group_id="O2" value="477" spread="1611"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of the summed volume of new FLAIR lesions in the NA-1 and placebo treated groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.445</p_value>
            <method>ANCOVA</method>
            <method_desc>Data were cubic root transformed and modelled with multiple linear regression.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of New DWI Lesions (MRI)</title>
        <description>Number of new ischemic lesions as defined by DWI MRI at 12-95 hours postdose.</description>
        <time_frame>Enrolment, Day 2-4</time_frame>
        <population>All patients who received study drug and an analyzable MRI at 12-95 hours postdose.</population>
        <group_list>
          <group group_id="O1">
            <title>1 NA-1</title>
            <description>20 amino acid peptide that consists of a 9 amino acid domain that inhibits PSD-95 and a 11 amino acid domain than enables the peptide to cross the blood-brain barrier.
NA-1 : single intravenous dose of 2.6 mg/kg of NA-1 administered as a 10-minute infusion</description>
          </group>
          <group group_id="O2">
            <title>2 Placebo</title>
            <description>Placebo : single intravenous dose of 2.6 mg/kg of placebo administered as a 10-minute infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Number of New DWI Lesions (MRI)</title>
          <description>Number of new ischemic lesions as defined by DWI MRI at 12-95 hours postdose.</description>
          <population>All patients who received study drug and an analyzable MRI at 12-95 hours postdose.</population>
          <units>Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="6.8"/>
                    <measurement group_id="O2" value="7.3" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of the total number of new ischemic lesions on DWI for NA-1 versus placebo treated groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.018</p_value>
            <method>Generalized linear model</method>
            <method_desc>With log link and negative bnomial distribution.</method_desc>
            <param_type>Adjusted Incidence Rate Ratio</param_type>
            <param_value>0.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.38</ci_lower_limit>
            <ci_upper_limit>0.74</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of New FLAIR Lesions (MRI)</title>
        <description>Number of new ischemic lesions as defined by FLAIR MRI at 12-95 hours postdose.</description>
        <time_frame>Enrolment, Days 2-4</time_frame>
        <population>All patients who received study drug and an analyzable MRI scan at 12-95 hours postdose.</population>
        <group_list>
          <group group_id="O1">
            <title>1 NA-1</title>
            <description>20 amino acid peptide that consists of a 9 amino acid domain that inhibits PSD-95 and a 11 amino acid domain than enables the peptide to cross the blood-brain barrier.
NA-1 : single intravenous dose of 2.6 mg/kg of NA-1 administered as a 10-minute infusion</description>
          </group>
          <group group_id="O2">
            <title>2 Placebo</title>
            <description>Placebo : single intravenous dose of 2.6 mg/kg of placebo administered as a 10-minute infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Number of New FLAIR Lesions (MRI)</title>
          <description>Number of new ischemic lesions as defined by FLAIR MRI at 12-95 hours postdose.</description>
          <population>All patients who received study drug and an analyzable MRI scan at 12-95 hours postdose.</population>
          <units>Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="4.4"/>
                    <measurement group_id="O2" value="4.8" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of the total number of new FLAIR lesions in the NA-1 versus placebo treated groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.048</p_value>
            <method>Generalized linear model</method>
            <method_desc>With log link and negative binomial distribution.</method_desc>
            <param_type>Adjusted Incidence Rate Ratio</param_type>
            <param_value>0.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>0.83</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of New DWI Lesions (MRI)</title>
        <description>Volume of new DWI lesions as defined by MRI at 12-95 hours postdose.</description>
        <time_frame>Enrolment, Days 2-4</time_frame>
        <population>All patients who received study drug and an analyzable MRI at 12-95 hours postdose.</population>
        <group_list>
          <group group_id="O1">
            <title>1 NA-1</title>
            <description>20 amino acid peptide that consists of a 9 amino acid domain that inhibits PSD-95 and a 11 amino acid domain than enables the peptide to cross the blood-brain barrier.
NA-1 : single intravenous dose of 2.6 mg/kg of NA-1 administered as a 10-minute infusion</description>
          </group>
          <group group_id="O2">
            <title>2 Placebo</title>
            <description>Placebo : single intravenous dose of 2.6 mg/kg of placebo administered as a 10-minute infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of New DWI Lesions (MRI)</title>
          <description>Volume of new DWI lesions as defined by MRI at 12-95 hours postdose.</description>
          <population>All patients who received study drug and an analyzable MRI at 12-95 hours postdose.</population>
          <units>mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="966" spread="5266"/>
                    <measurement group_id="O2" value="645" spread="1382"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of the summed volume of new ischemic lesions on DWI.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.306</p_value>
            <method>ANCOVA</method>
            <method_desc>Data were cubic root transformed and modelled with multiple linear regresion.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>National Institutes of Health Stroke Scale (NIHSS).</title>
        <description>The NIHSS is a standardized neurological method to measure disability and recovery after stroke. Scores range from 0 to 42, with higher scores indicating increasing severity. Scores were dichotomized into 0-1 (good outcome) versus 2 or above. The number of participants scoring 0-1 on the NIHSS at Day 30 was compared for both groups.</description>
        <time_frame>Enrolment, Day 30</time_frame>
        <population>All patients who received study drug and outcome assessment at Day 30.</population>
        <group_list>
          <group group_id="O1">
            <title>1 NA-1</title>
            <description>20 amino acid peptide that consists of a 9 amino acid domain that inhibits PSD-95 and a 11 amino acid domain than enables the peptide to cross the blood-brain barrier.
NA-1 : single intravenous dose of 2.6 mg/kg of NA-1 administered as a 10-minute infusion</description>
          </group>
          <group group_id="O2">
            <title>2 Placebo</title>
            <description>Placebo : single intravenous dose of 2.6 mg/kg of placebo administered as a 10-minute infusion</description>
          </group>
        </group_list>
        <measure>
          <title>National Institutes of Health Stroke Scale (NIHSS).</title>
          <description>The NIHSS is a standardized neurological method to measure disability and recovery after stroke. Scores range from 0 to 42, with higher scores indicating increasing severity. Scores were dichotomized into 0-1 (good outcome) versus 2 or above. The number of participants scoring 0-1 on the NIHSS at Day 30 was compared for both groups.</description>
          <population>All patients who received study drug and outcome assessment at Day 30.</population>
          <units>No. of participants with NIHSS 0-1</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" lower_limit="0.9" upper_limit="1.1"/>
                    <measurement group_id="O2" value="83" lower_limit="0.9" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Number of patients obtaining a score on the NIHSS of 0-1 at Day 30.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.43</p_value>
            <method>Chi-squared</method>
            <param_type>Relative Risk</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Rankin Scale (mRS).</title>
        <description>The mRS is a measure of global disability that has been widely applied for evaluating recovery from stroke. Scores range from 0 to 6, with higher scores indicating greater disability. A score of 0 indicates no residual symptoms; 1 = no significant disability/able to carry out all usual activities, despite some symptoms; 2 = slight disability; 3 = moderate disability; 4 = moderately severe disability; 5 = severe disability; 6 = death. The number of participants scoring 0-2 on the mRS at Day 30 was compared in both treatment groups.</description>
        <time_frame>Enrolment, Day 30</time_frame>
        <population>All patients who received study drug and an outcome assessment at Day 30</population>
        <group_list>
          <group group_id="O1">
            <title>1 NA-1</title>
            <description>20 amino acid peptide that consists of a 9 amino acid domain that inhibits PSD-95 and a 11 amino acid domain than enables the peptide to cross the blood-brain barrier.
NA-1 : single intravenous dose of 2.6 mg/kg of NA-1 administered as a 10-minute infusion</description>
          </group>
          <group group_id="O2">
            <title>2 Placebo</title>
            <description>Placebo : single intravenous dose of 2.6 mg/kg of placebo administered as a 10-minute infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Rankin Scale (mRS).</title>
          <description>The mRS is a measure of global disability that has been widely applied for evaluating recovery from stroke. Scores range from 0 to 6, with higher scores indicating greater disability. A score of 0 indicates no residual symptoms; 1 = no significant disability/able to carry out all usual activities, despite some symptoms; 2 = slight disability; 3 = moderate disability; 4 = moderately severe disability; 5 = severe disability; 6 = death. The number of participants scoring 0-2 on the mRS at Day 30 was compared in both treatment groups.</description>
          <population>All patients who received study drug and an outcome assessment at Day 30</population>
          <units>No. of participants with mRS 0-2</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" lower_limit="0.9" upper_limit="1.1"/>
                    <measurement group_id="O2" value="87" lower_limit="0.9" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of the number of patients with mRS scores of 0-2 at Day 30 for NA-1 and placebo treated groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.00</p_value>
            <method>Chi-squared</method>
            <param_type>Relative Risk</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Volume of New FLAIR Lesions (MRI) - Ruptured Aneurysm Subjects</title>
        <description>Volume of new ischemic lesions as defined by FLAIR MRI at 12-95 hours postdose (pre-specified subgroup analysis)</description>
        <time_frame>Enrolment, Days 2-4</time_frame>
        <population>All subjects who entered the study with a ruptured aneurysm, who received study drug and an analyzable MRI at 12-95 hours postdose.</population>
        <group_list>
          <group group_id="O1">
            <title>1 NA-1 - Subjects With Ruptured Aneurysms</title>
            <description>20 amino acid peptide that consists of a 9 amino acid domain that inhibits PSD-95 and a 11 amino acid domain than enables the peptide to cross the blood-brain barrier.
NA-1 : single intravenous dose of 2.6 mg/kg of NA-1 administered as a 10-minute infusion</description>
          </group>
          <group group_id="O2">
            <title>2 Placebo - Subjects With Ruptured Aneurysms</title>
            <description>Placebo : single intravenous dose of 2.6 mg/kg of placebo administered as a 10-minute infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of New FLAIR Lesions (MRI) - Ruptured Aneurysm Subjects</title>
          <description>Volume of new ischemic lesions as defined by FLAIR MRI at 12-95 hours postdose (pre-specified subgroup analysis)</description>
          <population>All subjects who entered the study with a ruptured aneurysm, who received study drug and an analyzable MRI at 12-95 hours postdose.</population>
          <units>mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205" spread="495"/>
                    <measurement group_id="O2" value="1575" spread="3229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.023</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of New DWI Lesions (MRI) - Ruptured Aneuryms Subjects</title>
        <description>Number of new ischemic lesions as defined by DWI MRI at 12-95 hours postdose(pre-specified subgroup analysis)</description>
        <time_frame>Enrolment, Day 2-4</time_frame>
        <population>All subjects who entered the study with a ruptured aneurysm, who received study drug and an analyzable MRI at 12-95 hours postdose.</population>
        <group_list>
          <group group_id="O1">
            <title>1 NA-1 - Subjects With Ruptured Aneurysms</title>
            <description>20 amino acid peptide that consists of a 9 amino acid domain that inhibits PSD-95 and a 11 amino acid domain than enables the peptide to cross the blood-brain barrier.
NA-1 : single intravenous dose of 2.6 mg/kg of NA-1 administered as a 10-minute infusion</description>
          </group>
          <group group_id="O2">
            <title>2 Placebo - Subjects With Ruptured Aneurysms</title>
            <description>Placebo : single intravenous dose of 2.6 mg/kg of placebo administered as a 10-minute infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Number of New DWI Lesions (MRI) - Ruptured Aneuryms Subjects</title>
          <description>Number of new ischemic lesions as defined by DWI MRI at 12-95 hours postdose(pre-specified subgroup analysis)</description>
          <population>All subjects who entered the study with a ruptured aneurysm, who received study drug and an analyzable MRI at 12-95 hours postdose.</population>
          <units>Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="5.9"/>
                    <measurement group_id="O2" value="9.47" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.027</p_value>
            <method>Adjusted Incidence Rate Ratio</method>
            <param_type>Adjusted Incidence Rate Ratio</param_type>
            <param_value>0.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.17</ci_lower_limit>
            <ci_upper_limit>0.73</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of New FLAIR Lesions (MRI) - Ruptured Aneurysm Subjects</title>
        <description>Number of new ischemic lesions as defined by FLAIR MRI at 12-95 hours postdose(pre-specified subgroup analysis)</description>
        <time_frame>Enrolment, Day 2-4</time_frame>
        <population>All subjects who entered the study with a ruptured aneurysm, who received study drug and an analyzable MRI at 12-95 hours postdose.</population>
        <group_list>
          <group group_id="O1">
            <title>1 NA-1 - Subjects With Ruptured Aneurysms</title>
            <description>20 amino acid peptide that consists of a 9 amino acid domain that inhibits PSD-95 and a 11 amino acid domain than enables the peptide to cross the blood-brain barrier.
NA-1 : single intravenous dose of 2.6 mg/kg of NA-1 administered as a 10-minute infusion</description>
          </group>
          <group group_id="O2">
            <title>2 Placebo - Subjects With Ruptured Aneurysms</title>
            <description>Placebo : single intravenous dose of 2.6 mg/kg of placebo administered as a 10-minute infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Number of New FLAIR Lesions (MRI) - Ruptured Aneurysm Subjects</title>
          <description>Number of new ischemic lesions as defined by FLAIR MRI at 12-95 hours postdose(pre-specified subgroup analysis)</description>
          <population>All subjects who entered the study with a ruptured aneurysm, who received study drug and an analyzable MRI at 12-95 hours postdose.</population>
          <units>Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="4.7"/>
                    <measurement group_id="O2" value="6.58" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.046</p_value>
            <method>Generalized linear model</method>
            <param_type>Adjusted Incidence Rate Ratio</param_type>
            <param_value>0.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.17</ci_lower_limit>
            <ci_upper_limit>0.75</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Volume of New DWI Lesions (MRI) - Ruptured Aneurysm Subjects</title>
        <description>Volume of new DWI lesions as defined by MRI at 12-95 hours postdose(pre-specified subgroup analysis)</description>
        <time_frame>Enrolment, Day 2-4</time_frame>
        <population>All subjects who entered the study with a ruptured aneurysm, who received study drug and an analyzable MRI at 12-95 hours postdose.</population>
        <group_list>
          <group group_id="O1">
            <title>1 NA-1 - Subjects With Ruptured Aneurysms</title>
            <description>20 amino acid peptide that consists of a 9 amino acid domain that inhibits PSD-95 and a 11 amino acid domain than enables the peptide to cross the blood-brain barrier.
NA-1 : single intravenous dose of 2.6 mg/kg of NA-1 administered as a 10-minute infusion</description>
          </group>
          <group group_id="O2">
            <title>2 Placebo - Subjects With Ruptured Aneurysms</title>
            <description>Placebo : single intravenous dose of 2.6 mg/kg of placebo administered as a 10-minute infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of New DWI Lesions (MRI) - Ruptured Aneurysm Subjects</title>
          <description>Volume of new DWI lesions as defined by MRI at 12-95 hours postdose(pre-specified subgroup analysis)</description>
          <population>All subjects who entered the study with a ruptured aneurysm, who received study drug and an analyzable MRI at 12-95 hours postdose.</population>
          <units>mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="277" spread="528"/>
                    <measurement group_id="O2" value="1373" spread="2267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.015</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>National Institutes of Health Stroke Scale (NIHSS) - Ruptured Aneurysm Subjects</title>
        <description>The NIHSS is a standardized neurological method to measure disability and recovery after stroke. Scores range from 0 to 42, with higher scores indicating increasing severity. Scores were dichotomized into 0-1 (good outcome) versus 2 or above. The number of participants scoring 0-1 on the NIHSS at Day 30 was compared for participants with ruptured aneurysms in both treatment groups(pre-specified subgroup analysis).</description>
        <time_frame>Enrolment, Day 30</time_frame>
        <population>All subjects who entered the study with a ruptured aneurysm, who received study drug and outcome assessment at Day 30.</population>
        <group_list>
          <group group_id="O1">
            <title>1 NA-1 - Subjects With Ruptured Aneurysms</title>
            <description>20 amino acid peptide that consists of a 9 amino acid domain that inhibits PSD-95 and a 11 amino acid domain than enables the peptide to cross the blood-brain barrier.
NA-1 : single intravenous dose of 2.6 mg/kg of NA-1 administered as a 10-minute infusion</description>
          </group>
          <group group_id="O2">
            <title>2 Placebo - Subjects With Ruptured Aneurysms</title>
            <description>Placebo : single intravenous dose of 2.6 mg/kg of placebo administered as a 10-minute infusion</description>
          </group>
        </group_list>
        <measure>
          <title>National Institutes of Health Stroke Scale (NIHSS) - Ruptured Aneurysm Subjects</title>
          <description>The NIHSS is a standardized neurological method to measure disability and recovery after stroke. Scores range from 0 to 42, with higher scores indicating increasing severity. Scores were dichotomized into 0-1 (good outcome) versus 2 or above. The number of participants scoring 0-1 on the NIHSS at Day 30 was compared for participants with ruptured aneurysms in both treatment groups(pre-specified subgroup analysis).</description>
          <population>All subjects who entered the study with a ruptured aneurysm, who received study drug and outcome assessment at Day 30.</population>
          <units>No. of participants with NIHSS 0-1</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Chi-squared</method>
            <param_type>Relative Risk</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Modified Rankin Scale (mRS)- Ruptured Aneurysm Subjects</title>
        <description>The mRS is a measure of global disability that has been widely applied for evaluating recovery from stroke. Scores range from 0 to 6, with higher scores indicating greater disability. A score of 0 indicates no residual symptoms; 1 = no significant disability/able to carry out all usual activities, despite some symptoms; 2 = slight disability; 3 = moderate disability; 4 = moderately severe disability; 5 = severe disability; 6 = death. The number of participants scoring 0-2 on the mRS at Day 30 with ruptured aneurysms was compared in both treatment groups(pre-specified subgroup analysis).</description>
        <time_frame>Enrolment, Day 30</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 NA-1 - Subjects With Ruptured Aneurysms</title>
            <description>20 amino acid peptide that consists of a 9 amino acid domain that inhibits PSD-95 and a 11 amino acid domain than enables the peptide to cross the blood-brain barrier.
NA-1 : single intravenous dose of 2.6 mg/kg of NA-1 administered as a 10-minute infusion</description>
          </group>
          <group group_id="O2">
            <title>2 Placebo - Subjects With Ruptured Aneurysms</title>
            <description>Placebo : single intravenous dose of 2.6 mg/kg of placebo administered as a 10-minute infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Rankin Scale (mRS)- Ruptured Aneurysm Subjects</title>
          <description>The mRS is a measure of global disability that has been widely applied for evaluating recovery from stroke. Scores range from 0 to 6, with higher scores indicating greater disability. A score of 0 indicates no residual symptoms; 1 = no significant disability/able to carry out all usual activities, despite some symptoms; 2 = slight disability; 3 = moderate disability; 4 = moderately severe disability; 5 = severe disability; 6 = death. The number of participants scoring 0-2 on the mRS at Day 30 with ruptured aneurysms was compared in both treatment groups(pre-specified subgroup analysis).</description>
          <units>No. of participants with mRS 0-2</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.18</p_value>
            <method>Chi-squared</method>
            <param_type>Relative Risk</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>1 NA-1</title>
          <description>20 amino acid peptide that consists of a 9 amino acid domain that inhibits PSD-95 and a 11 amino acid domain than enables the peptide to cross the blood-brain barrier.
NA-1 : single intravenous dose of 2.6 mg/kg of NA-1 administered as a 10-minute infusion</description>
        </group>
        <group group_id="E2">
          <title>2 Placebo</title>
          <description>Placebo : single intravenous dose of 2.6 mg/kg of placebo administered as a 10-minute infusion</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Administration site</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural complications</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="92"/>
                <counts group_id="E2" events="14" subjects_affected="9" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Genitourinary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="92"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="33" subjects_affected="33" subjects_at_risk="92"/>
                <counts group_id="E2" events="28" subjects_affected="27" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="92"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="92"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Puncture site pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="92"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="92"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="92"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="92"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="92"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="47" subjects_affected="42" subjects_at_risk="92"/>
                <counts group_id="E2" events="39" subjects_affected="37" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="92"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="92"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="92"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="92"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="92"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="92"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="92"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="92"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Investigator shall have the right to publish any information after prior submittal to NoNO, where NoNO can request a hold for up to 60 days, provided that no publication shall disclose Proprietary Information other than Data containing the results of the Study. Investigators may not publish in the first 18 months after the close of the trial except within a publication representing all participating clinical sites.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Roberta Anderson, Vice President of Clinical Development</name_or_title>
      <organization>NoNO Inc.</organization>
      <phone>613 833-1020</phone>
      <email>randerson@nonoinc.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

